NCT00160602

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 590 (planned)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Certolizumab Pegol

Timeline

• Start date: 2005-06-01
• Primary completion: 2006-09-01
• Completion: 2006-09-01
• First posted: 2005-09-12
• Last updated: 2020-12-01

Locations

70 sites across 15 countries: United States, Bulgaria, Chile, Croatia, Czechia, Estonia, Israel, Latvia, Lithuania, Mexico, Poland, Russia, Serbia, Slovakia, Ukraine